Intravenous therapy for the treatment of multiple sclerosis

Multiple Sclerosis (MS) is a multi‐focal disease of the central nervous system (CNS) that is characterised by inflammation, demyelination and axonal degeneration. In the majority of MS patients, the disease presents with a relapsing remitting course at disease onset. Relapsing remitting MS (RRMS); affects around two thirds of the 85 000 people in the UK with MS.¹ The aims of treatment in RRMS are not only to prevent the rate of relapse, but also to slow down patients' disability progression. Copyright © 2007 Wiley Interface Ltd